Rubicon Research receives US FDA approval for its ANDA for Tizanidine Hydrochloride Capsules, 2 mg, 4 mg, and 6 mg
Thane, Mumbai (India), May 29, 2020Rubicon Research Pvt Ltd has received approval from the US Food and Drug Administration for its Abbreviated New Drug Application for Tizanidine Hydrochloride Capsules, in the strengths of 2 mg (base), 4 mg (base), and 6 mg (base). Tizanidine hydrochloride is a central alpha-2-adrenergic agonist indicated for the management of spasticity.
Rubicon Research receives US FDA approval for its ANDA for Amantadine Capsules USP, 100 mg
Thane, Mumbai (India), May 26, 2020Rubicon Research Pvt Ltd has received approval from the US Food and Drug Administration for its Abbreviated New Drug Application for Amantadine Capsules USP in the strength of 100 mg. Amantadine Hydrochloride, USP, is indicated for prophylaxis, and for the treatment of signs and symptoms of infection caused by various strains of influenza A virus, Parkinsonism, and drug-induced extrapyramidal reactions.
Rubicon Research Commits Rs 2 Crore for the Fight Against COVID-19
Thane, Mumbai (India), April 30, 2020Rubicon Research Pvt Ltd has committed Rs 2 crore to support India’s fight against the coronavirus pandemic. The support will be by way of a number of initiatives, including donating Rs 1.9 crore worth of Hydroxychloroquine (1.5 million tablets) and immunity boosting products to help frontline workers and high-risk patients.
Rubicon Research Acquires Impopharma Canada
Thane, Mumbai (India), 7th Jan 2020As part of its ongoing effort to establish a global development network, Rubicon Research Private Limited, a leading specialty pharmaceutical company, today announced the acquisition of Impopharma Canada Limited with operations in Ontario, Canada.
Rubicon Research Announces Commencement of Analytical Services
Thane, Mumbai (India), 2nd Sept 2019Rubicon announces offering of analytical services as standalone activity from its cGMP plant location. We base our approach on our expertise in Analytical Method Development and GMP Quality Control Testing. This service supplements our stability storage and stability samples analysis service from well controlled stability study infrastructure.
Rubicon Research and General Atlantic Announce Strategic Partnership
Thane, Mumbai (India), 8th Apr 2019Rubicon Research Pvt Ltd (“Rubicon”), a global leader in innovative pharmaceutical product development, announced today that General Atlantic has become a significant shareholder in the company. General Atlantic, a leading global growth equity firm, is committing up to $100 million of primary capital and has acquired the stake held by Rubicon’s existing private equity shareholders. All other existing shareholders continue to maintain their shareholding in the company.